AgomAb Therapeutics NV American Depositary Shares Cash Flow Conversion Efficiency
AgomAb Therapeutics NV American Depositary Shares cash flow conversion efficiency. Based on the latest financial reports, AgomAb Therapeutics NV American Depositary Shares (AGMB) has a cash flow conversion efficiency ratio of -0.085x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.44 Million) by net assets ($146.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of AgomAb Therapeutics NV American Deposita for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of AgomAb Therapeutics NV American Depositary Shares (2022–2025)
Cash flow conversion efficiency of AgomAb Therapeutics NV American Depositary Shares from 2022 to 2025. This chart illustrates how AgomAb Therapeutics NV American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AgomAb Therapeutics NV American Deposita stock price for real-time trading data and today's change.
AgomAb Therapeutics NV American Depositary Shares Cash Flow Conversion Ratio Explained
AgomAb Therapeutics NV American Depositary Shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
AgomAb Therapeutics NV American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AgomAb Therapeutics NV American Depositary Shares ranked by their cash flow conversion efficiency. Review AgomAb Therapeutics NV American Deposita (AGMB) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Northeast Community Bancorp Inc
NASDAQ:NECB
|
0.035x |
|
Focus Minerals Ltd
AU:FML
|
0.372x |
|
Analyst IMS Investment Management Services Ltd
TA:ANLT
|
0.043x |
|
SVI Public Company Limited
BK:SVI
|
0.060x |
|
Aprogen KIC Inc
KO:007460
|
-0.041x |
|
China Lilang Limited
F:5LX
|
0.069x |
|
Kretam Holdings Bhd
KLSE:1996
|
0.152x |
|
Jinsanjiang (Zhaoqing) Silicon Material Company Limited
SHE:301059
|
N/A |
Annual Cash Flow Conversion Efficiency for AgomAb Therapeutics NV American Depositary Shares (2022–2025)
The table below shows the annual cash flow conversion efficiency of AgomAb Therapeutics NV American Depositary Shares from 2022 to 2025. Also see AGMB asset base for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $130.90 Million | $-51.74 Million | -0.395x | -58.76% |
| 2024-12-31 | $188.08 Million | $-46.83 Million | -0.249x | -53.32% |
| 2023-12-31 | $151.44 Million | $-24.59 Million | -0.162x | +43.28% |
| 2022-12-31 | $66.25 Million | $-18.97 Million | -0.286x | -- |
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinica… Read more